G1 Therapeutics Stock Profit Margin

GTHXDelisted Stock  USD 7.15  0.00  0.00%   
G1 Therapeutics fundamentals help investors to digest information that contributes to G1 Therapeutics' financial success or failures. It also enables traders to predict the movement of GTHX Stock. The fundamental analysis module provides a way to measure G1 Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to G1 Therapeutics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

G1 Therapeutics Company Profit Margin Analysis

G1 Therapeutics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Profit Margin

 = 

Net Income

Revenue

X

100

More About Profit Margin | All Equity Analysis

Current G1 Therapeutics Profit Margin

    
  (0.77) %  
Most of G1 Therapeutics' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, G1 Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition

Based on the latest financial disclosure, G1 Therapeutics has a Profit Margin of -0.7693%. This is 93.14% lower than that of the Biotechnology sector and 96.66% lower than that of the Health Care industry. The profit margin for all United States stocks is 39.43% lower than that of the firm.

GTHX Profit Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses G1 Therapeutics' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of G1 Therapeutics could also be used in its relative valuation, which is a method of valuing G1 Therapeutics by comparing valuation metrics of similar companies.
G1 Therapeutics is currently under evaluation in profit margin category among its peers.

GTHX Fundamentals

About G1 Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze G1 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of G1 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of G1 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Consideration for investing in GTHX Stock

If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Global Correlations
Find global opportunities by holding instruments from different markets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing